E m e r g i n g T r e a t m e n t s a n d T e c h n o l o g i e s
Effect of High-Dose Vitamin E on Insulin
Resistance and Associated Parameters in
Overweight Subjects
implicated in the pathogenesis of insulin AYNE H.F. SUTHERLAND, PHD
resistance is the free fatty acid (FFA) (7).
Although the rate of release of FFAs from HEILA M. WILLIAMS, MSC
individual adipocytes may not be raisedin obesity, the increased amount of adi-pose tissue overall leads to an increase inthe flux of FFAs to the liver and skeletalmuscle, the two tissues most intimately OBJECTIVE — Markers of oxidative stress and plasma alanine transferase (ALT) levels are
increased and circulating antioxidant concentrations are reduced in individuals with insulin FFAs enter target tissues, they are either resistance. Vitamin E improves glycemic control in people with diabetes. We tested the hypoth-esis that vitamin E would decrease markers of oxidative stress and plasma ALT levels and stored as triglycerides or are utilized as a improve insulin sensitivity in overweight individuals.
substrate for oxidation by the cell’s mito-chondria. As a result of the normal pro- RESEARCH DESIGN AND METHODS — Eighty overweight individuals (BMI Ͼ27
cess of oxidation, reactive oxygen species kg/m2) were randomly allocated to receive either 800 IU vitamin E per day or a matching placebo for 3 months. The dose of vitamin E was increased to 1,200 IU per day for a further 3 months.
potentially harmful to cellular functions.
To prevent these harmful effects, the cell RESULTS — Plasma peroxides decreased by 27% at 3 months and by 29% at 6 months in the
group that received vitamin E and were positively correlated with plasma vitamin E concentra- tions at the 6-month time point. At 3 months, fasting plasma glucose and insulin concentrations idant concentrations are reduced in obese were significantly reduced and homeostasis model assessment increased. These changes werenot apparent at 6 months. Plasma ALT concentrations declined significantly throughout the between the production of ROS and anti-oxidant defenses results in oxidative CONCLUSIONS — In conclusion, these findings indicate that vitamin E improves oxidative
stress (10). Although the relationship be- stress and hepatocellular function. Although insulin resistance also improves, this effect appears tween oxidative stress and certain diabe- tes-related complications has been firmlyestablished (11), there is still uncertainty Diabetes Care 27:2166 –2171, 2004
concerning its role in the development ofinsulin resistance.
Theprevalenceofdiabetesisincreas- factorsisalteredintheobeseindividual inglucosehomeostasis,andhepaticinsu-
(3). Diabetes results when, in addition to lin sensitivity is of profound importance in determining fasting glucose concentra- that of obesity, with insulin resistance ex- occurs, leading to relative insulin defi- plaining the link between these two enti- ␥-glutamyl transferase (GGT) predict fu- responsible for insulin resistance remains ture risk of developing diabetes (12).
unclear, it would appear that a number of antioxidant activity. Systemic concentra- ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● From the 1Department of Medical and Surgical Sciences, Dunedin School of Medicine, University of Otago, individuals probably reflect nonalcoholic Dunedin, New Zealand; and the 2Department of Preventive and Social Medicine, Dunedin School of Med- fatty liver disease, which is itself a marker icine, University of Otago, Dunedin, New Zealand.
of insulin resistance (13). Whether anti- Address correspondence and reprint requests to Dr. Patrick J. Manning, Department of Medical and Surgical Sciences, University of Otago, Private bag, Dunedin, New Zealand. E-mail: patrickmanning@ Received for publication 4 April 2004 and accepted in revised form 15 June 2004.
tions in obese individuals is uncertain.
Abbreviations: ALT, alanine transferase; AST, aspartate aminotransferase; CRP, C-reactive protein; FFA,
free fatty acid; GGT, ␥-glutamyl transferase; HOMA, homeostasis model assessment; IL, interleukin; ROS, to improve insulin signaling in vitro (14) reactive oxygen species; TNF, tumor necrosis factor.
and improves glycemic control in individ- A table elsewhere in this issue shows conventional and Syste`me International (SI) units and conversion 2004 by the American Diabetes Association.
DIABETES CARE, VOLUME 27, NUMBER 9, SEPTEMBER 2004 Manning and Associates
correlation coefficients were used to test insulin sensitivity and/or the other meta- for relationships between variables.
resistance. This study was designed to in- RESULTS — Six subjects dropped out
agnostic Laboratories, Dunedin Hospital.
from the study for personal reasons before RESEARCH DESIGN AND
METHODS — Eighty-six healthy sub-
characteristics of the remaining 80 partic- jects, aged 31– 65 years, with a BMI Ͼ27 cant differences existed in any variables (IL)-6 and tumor necrosis factor (TNF)-␣ centrations at baseline were Ͼ35 IU/l in 10, 7, and 14 subjects, respectively. Self- supplements, serious illness, and clinical that 55% of participants did not drink al- ric, health, and lifestyle information was collected. Participants gave informed and method is based on the cleavage of perox- the initial 3 months but gave blood at all ides by horseradish peroxidase, leading to randomization with stratification for sex count indicated that 84% of subjects dur- calibrator (Roche Diagnostics). As deter- Ͻ25 kg/m2) is 27.2 (21.7–48.5) pmol/l. during the study.
creased significantly in participants who cebo for a further 3 months. Subjects were ␣-tocopherol concentration was mea- were randomized to vitamin E treatment and did not change significantly in those receiving placebo (Fig. 1). Despite an in- the same assay to reduce interassay varia- crease in vitamin E dosage in the final 3 months of the study, circulating vitamin E plasma insulin, CRP, IL-6, TNF-␣, perox- searcher (W.H.F.S.), who did not interact index of insulin sensitivity was calculated (fasting glucose ϫ fasting insulin).
tion was carried out in blocks of six. Par- lifestyle changes during the study. Assess- Values are given as median (interquartile glucose, insulin, and peroxide concentra- tions were significantly less than zero and significantly greater than zero. Plasma tri- that accounted for the underlying covari- ance structure in the data and adjusted for the baseline measures was used to analyze variables were significantly different from for all variables, the results being reported tubes, the tubes were then centrifuged at 1,500g for 15 min at 4°C, and plasma and DIABETES CARE, VOLUME 27, NUMBER 9, SEPTEMBER 2004 Vitamin E and insulin resistance
Table 1—Characteristics of the subjects at baseline
39). After lipid standardization, the re-sults remained unchanged, although thecorrelation between baseline vitamin E statistically significant (r ϭ Ϫ0.120, CONCLUSIONS — Oxidative stress
studies but not all (20), antioxidant ther- type 2 diabetes (15,16). In addition, anti- reduced in individuals at increased risk of antioxidant therapy improves insulin sen- sitivity in nondiabetic individuals who are obese. Our results suggest that vitamin E improves insulin sensitivity and the asso- Data are median (interquartile range).
the magnitude of this improvement in in-sulin sensitivity, as indicated by fastinginsulin levels, depends on the magnitude of the increase in plasma vitamin E. It is was significantly correlated with the in- well established that fasting insulin and at 6 months (r ϭ Ϫ0.404, P ϭ 0.01, n ϭ sulin sensitivity and correlate well with 95% CIs, for plasma ALT, GGT, and ASTconcentrations at 3 months and 6 monthsare shown in Fig. 3. The differences forplasma ALT at 3 and 6 months were sig-nificantly different from zero. The corre-sponding differences for plasma GGT andAST were close to attaining statistical sig-nificance from zero.
body weight (P ϭ 0.77), BMI (P ϭ 0.87),blood pressure, and plasma concentra-tions of cholesterol, HDL cholesterol,HbA1c, CRP, IL-6, and TNF-␣ did notchange significantly in subjects receivingvitamin E compared with placebo duringthe study.
concentration was significantly correlatedwith the increase in plasma vitamin Econcentration during the initial 3 monthsof the study (r ϭ Ϫ0.235, n ϭ 80, P ϭ0.04). Plasma peroxide concentrationswere correlated significantly with plasmavitamin E concentration at baseline (r ϭ Figure 1—Plasma concentration of vitamin E in participants receiving vitamin E (f) or placebo Ϫ0.272, P ϭ 0.015, n ϭ 80). The de- () during the study. Values are mean Ϯ SE. DIABETES CARE, VOLUME 27, NUMBER 9, SEPTEMBER 2004 Manning and Associates
dylinositol 3-kinase– catalyzed phos-phorylation of tyrosine residues in theseproteins, which is required for effectiveinsulin action. Recent evidence (28) sug-gests that vitamin E may influence the ac-tivity of these enzymes by decreasing thecurvature of plasma membranes.
glucose and insulin metabolism. It is themain site of insulin clearance from theblood (29). Animal studies (30) showthat genetic knockout of hepatic insulinreceptors results in severe insulin resis- tance, hyperinsulinemia, glucose intoler- ance, and severe hepatic dysfunction.
ated with hepatic insulin resistance (31) HOMA at 3 () and 6 (f) and elevated levels of hepatic enzymes in the blood. Furthermore, in nondiabeticindividuals, plasma ALT is associated with percentage of body fat, hepatic insu- lin resistance, and hepatic glucose output in insulin sensitivity in elderly subjects protection by regulating intracellular lev- the cellular level that are not dependent on its antioxidant activity and may poten- output is the main determinant of fasting tially contribute to improved insulin ac- blood glucose levels. High-dose vitamin E onstrating this effect in obese nondiabetic els of plasma hepatic enzymes in patients with nonalcoholic fatty liver disease (33).
ates diacylglycerol kinase activity, thereby decreasing levels of diacylglycerol, which cose levels by decreasing cellular oxidant is an allosteric activator of protein kinase stress, altering membrane properties, and C (26). Increased protein kinase C activity possible that the concomitant decrease in fasting insulin and glucose levels may be phosphorylating serine or threonine resi- due to, at least in part, improved hepato- insulin resistance and glucose output.
in the chemical-physical state of plasmamembranes as a result of a decrease inoxidative stress. Red cell membrane fluid-ity decreased in association with a de-crease in the ratio of serum oxidized toreduced glutathione and concomitantlywith an increase in insulin sensitivity dur-ing 4 months of vitamin E treatment inelderly subjects (22). In addition, in-creased vitamin E may enhance the en-dogenous cellular antioxidant defensesystem and reduce levels of ROS that areproduced by mitochondria. IncreasedFFA levels may overload the mitochon-drial oxidation process, leading to accel-erated production of ROS (7) andincreased oxidant stress in obese individ- Figure 3—Treatment-placebo differ- uals (10). Peroxides are ROS and interfere ence and 95% CIs for plasma ALT, GGT, with insulin signaling (24). In the present and AST activities at 3 () and 6 (f) DIABETES CARE, VOLUME 27, NUMBER 9, SEPTEMBER 2004 Vitamin E and insulin resistance
cient evidence to exclude a clinically im- portant effect of vitamin E, and a larger sulin resistance. Studies from our labora- study is required to clarify this issue.
incidence of type 2 diabetes with lifestyle described as being associated with insulin intervention or metformin. N Engl J Med346:393– 403, 2002 5. Tuomilehto J, Lindstrom J, Eriksson JG, associations have given rise to the meta- jects in this study did not necessarily meet the effects of vitamin E on its component tion, during vitamin E supplementation.
tes mellitus by changes in lifestyle among These findings suggest that changes in in- an improvement in insulin sensitivity, we subjects with impaired glucose tolerance.
N Engl J Med 344:1343–1350, 2001 triglycerides at 3 months. This effect had 6. Buchanan TA, Xiang AH, Peters RK, Kjos sitivity noted during vitamin E treatment.
sistent with the waning effect of vitamin E ervation of pancreatic ␤-cell function and cological treatment of insulin resistance in identified, these were not significant. No high-risk Hispanic women. Diabetes 51: this observation. Pill count did not sug- 7. McGarry JD: Banting Lecture 2001: dys- regulation of fatty acid metabolism in the intestinal absorption of vitamin E is al- makes it unlikely that other factors had a etiology of type 2 diabetes. Diabetes 51:7– ready saturated at a dose of 800 IU/day. In significant influence on this finding.
8. Boden G, Shulman GI: Free fatty acids in obesity and type 2 diabetes: defining their logical effects of vitamin E, indicated by proves insulin sensitivity and several of its role in the development of insulin resis- associated parameters in overweight indi- tance and beta-cell dysfunction. Eur J Clin viduals, but the effect of treatment is not Invest 32 (Suppl. 3):14 –23, 2002 ing this period. This finding suggests that 9. Evans JL, Goldfine ID, Maddux BA, Grod- creased circulating levels of ALT, a risk factor for the development of type 2 dia- role in the improvement in insulin sensi- resistance and ␤-cell dysfunction? Diabe- tivity with vitamin E treatment. We noted results suggest that vitamin E could have a a trend to an increase in circulating FFAs role to play in delaying the onset of dia- tentially adversely affect insulin action (7). These observations, which are in con- Examination Survey. Diabetes 52:2346 – References
need further investigation. We cannot ex- 11. Brownlee M: Biochemistry and molecular clude the possibility that in the present cell biology of diabetic complications. Na- study the increase in the dose of vitamin E from 800 to 1,200 IU/day during the final 12. Vozarova B, Stefan N, Lindsay RS, Saremi impaired glucose tolerance in U.S. adults: deterioration in insulin sensitivity over Examination Survey, 1988 –1994. Diabe- ated with decreased hepatic insulin sensi- hoc analysis to investigate the possibility 2. Edelstein SL, Knowler WC, Bain RP, An- type 2 diabetes. Diabetes 51:1889 –1895, detect a significant improvement in insu- Haffner SM, Pettitt DJ, Sorkin JD, Muller 13. Angulo P: Nonalcoholic fatty liver dis- lin sensitivity. Samples of the size used in ease. N Engl J Med 346:1221–1231, 2002 this study, given the variability of the con- of progression from impaired glucose tol- trol group, have an 80% chance of detect- spective studies. Diabetes 46:701–710, tection against oxidative stress–induced in glucose using the 5% level of signifi- insulin resistance in rat L6 muscle cells by cance. Although the estimates of the effect 3. Greenberg AS, McDaniel ML: Identifying the links between obesity, insulin resis- acid. Diabetes 50:404 – 410, 2001 of vitamin E were not statistically signifi- tance and beta cell function: potential role 15. Paolisso G, D’Amore A, Galzerano D, Balbi cant in the last period of the study, the CIs V, Giugliano D, Varricchio M, D’Onofrio F: show that effects of a magnitude similar to pathogenesis of type 2 diabetes. Eur J Clin those in the first follow-up period cannot Invest 32 (Suppl. 3):24 –34, 2002 abolic control but not insulin secretion in elderly type II diabetic patients. Diabetes DIABETES CARE, VOLUME 27, NUMBER 9, SEPTEMBER 2004 Manning and Associates
23. Paolisso G, Giugliano D: Oxidative stress 31. Garg A, Misra A: Hepatic steatosis, insulin 16. Jacob S, Ruus P, Hermann R, Tritschler and insulin action: is there a relationship? resistance, and adipose tissue disorders.
J Clin Endocrinol Metab 87:3019 –3022, 24. Hansen LL, Ikeda Y, Olsen GS, Busch AK, RAC-␣-lipoic acid modulates insulin sen- Mosthaf L: Insulin signaling is inhibited 32. Griffith OW, Bridges RJ, Meister A: Evi- sitivity in patients with type 2 diabetes by micromolar concentrations of H2O2.
mellitus: a placebo-controlled pilot trial.
J Biol Chem 274:25078 –25084, 1999 functions in vivo using intracellular glu- Free Radic Biol Med 27:309 –314, 1999 25. Azzi A, Ricciarelli R, Zingg JM: Non-anti- tathione: effects of amino acids and selec- tive inhibition of enzymes. Proc Natl Acad tocopherol (vitamin E). FEBS Lett 519:8 – peroxides-iodide leads to a significant in- 26. Azzi A, Breyer I, Feher M, Pastori M, Ric- ciarelli R, Spycher S, Staffieri M, Stocker sera. Anal Biochem 316:147–153, 2003 tients with nonalcoholic steatohepatitis.
18. Sloan JC, Lappin TRJ: Automated colori- responses to alpha-tocopherol. J Nutr Am J Gastroenterol 98:2485–2490, 2003 34. Upritchard JE, Sutherland WH, Mann JI: erol. Clin Chim Acta 119:197–207, 1982 27. Griffin ME, Marcucci MJ, Cline GW, Bell fatty acid-induced insulin resistance is as- activity in type 2 diabetes. Diabetes Care index derived from oral glucose tolerance sociated with activation of protein kinase test. J Clin Endocrinol Metab 88:1019 – C␪ and alterations in the insulin signaling 35. Devaraj S, Jialal I: Alpha tocopherol sup- cascade. Diabetes 48:1270 –1274, 1999 20. Skrha J, Sindelka G, Kvasnicka J, Hilger- 28. Bradford A, Atkinson J, Fuller N, Rand tova J: Insulin action and fibrinolysis in- RP: The effect of vitamin E on the struc- ture of membrane lipid assemblies. J Lipid betic patients. Free Radic Biol Med 29: diabetes mellitus. Diabetes Res Clin Pract 36. Expert Panel on Detection, Evaluation, 21. Ferrannini E, Mari A: How to measure in- Hepatic metabolism of insulin. Am J Med sulin resistance. J Hypertens 16:895–906, 30. Michael MD, Kulkarni RN, Postic C, Pre- 22. Paolisso G, Di Maro G, Galzerano D, Cac- D’Onofrio F: Pharmacological doses of vi- hepatocytes leads to severe insulin resis- tamin E and insulin action in elderly sub- (Adult Treatment Panel III). JAMA 285: jects. Am J Clin Nutr 59:1291–1296, 1994 DIABETES CARE, VOLUME 27, NUMBER 9, SEPTEMBER 2004

Source: http://www.otagodiabetesresearch.org.nz/pdfs/VitEpaper.pdf


THE NUTRI-SPEC LETTER Volume 17 Number 12 From: Guy R. Schenker, D.C. December, 2006 Dear Doctor, BITS & PIECES, ODDS & BEGINNINGS. This has been an amazing year for NUTRI-SPEC doctors. --- It is truly gratifying to witness the quality and quantity of service you are providing. KEEP UP THE GOOD WORK … The world needs your systematic, objective approach

Roneo mycolo

Mycologie médicale Place des champignons dans le monde du vivant :Grande diversité du règne fongique : Macromycètes : non concernés en pathologie humaine sauf les cas de mycoses invasives à coprinus (1 fois tous les 10 ans, chez les immunodéprimés)Micromycètes : moisissures (penicilliniums) ; aspergillus et dermatophytes éfinitions : Ce sont des microorganisme uni- ou plurice

Copyright © 2010-2014 Medical Pdf Finder